Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

What Was Tested

The paper reports a study of Semaglutide in the context of fat loss, obesity & body recomposition, published as a randomized controlled trial.

Here in this prespecified analysis, the researchers examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI).

In patients treated with semaglutide, weight loss continued over 65 weeks and was sustained for up to 4 years.

Who Took Part

The study group was 17,604 adults.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the adults nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Semaglutide could be set against what happens without it.

The timeline in the abstract includes 65 weeks.

What Was Measured

Here in this prespecified analysis, the researchers examined effects of semaglutide on weight and anthropometric outcomes, safety and tolerability by baseline body mass index (BMI).

The subject headings attached to it are Glucagon-Like Peptides, Weight Loss, Obesity, Body Mass Index, Cardiovascular Diseases and Semaglutide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide in 17,604 adults in people with fat loss, obesity & body recomposition over 65 weeks.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2024 (Nature medicine), a journal based in United States.

More context: the Semaglutide compound page, Fat loss, obesity & body recomposition research.